PHAT (Phathom Corp) Earnings per share for the last four quarters

The successful promotion of new drugs and the capture of market niches support an upward annual shift in EPS TTM, where the metric level stands at 72.90. The strategy of Phathom Pharmaceuticals (PHAT) relies on outsourcing production to third-party factories and an organic sales relaunch without mergers. This earnings per share trend allows for a comparison of the business's fundamental growth with the company's current market capitalization.
Financial and market metric breakdowns for Phathom Corp (PHAT)

Professional managers utilize fundamental filters to evaluate the efficiency of profit capitalization, where net income per share (TTM) growth rates serve as an indicator of operational resilience. This trend reflects the commercial success of innovative drugs for the treatment of esophagitis, allowing the relative EPS YoY TTM chart to identify valuation pivot points for Phathom Pharmaceuticals (PHAT).